Program
Anti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101
Also written as “TJ101”, “TJ101 injection Test Product” and “TJ101 injection Reference Product”.
Its studies are mostly in Lung Neoplasms, led by 2 companies.
Drug pageAnti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| TJ Biopharmaits history only | 20 open or running | phase 3since Nov 12, 2020 | Nov 12, 2020 | none ahead |
| Phrontline Biopharmaits history only | 11 open or running | phase 1since Sep 1, 2025 | Sep 1, 2025 | Dec 30, 2026phase 1 · NCT07181473 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 12, 2020First study: phase 3 study in Pediatric Growth Hormone DeficiencyNew to TJ BiopharmaTJ Biopharma · NCT04633057 · 168 enrolled · China
- Sep 1, 2025Phrontline Biopharma’s first study: phase 1 study in Lung NeoplasmsNew to Phrontline BiopharmaPhrontline Biopharma · NCT07181473 · 200 planned · United States, China
- Dec 10, 2025Phase 1 study in Healthy Adult Males in ChinaTJ Biopharma · NCT07300436 · 96 enrolled · China
Ahead
- Dec 30, 2026Primary completion: phase 1 study in Lung NeoplasmsPhrontline Biopharma · NCT07181473
TargetBeta
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) bispecific antibody directed against the tumor associated antigens (TAAs) human epidermal growth factor receptor (EGFR) and B7-homologue 3 (B7-H3, CD276) ”NCIt, by rule
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07300436Healthy Adult Males in China · China | 1 | Completed | TJ Biopharma | Mar 16, 2026 | 96 |
| NCT07181473Lung Neoplasms · United States, China | 1 | Recruiting | Phrontline Biopharma | Dec 30, 2026 | 200 |
| NCT04633057Pediatric Growth Hormone Deficiency · China | 3 | Completed | TJ Biopharma | Jul 31, 2023 | 168 |
How it is read
Names in the registry
- “TJ101”, 2 entries
- “TJ101 injection Test Product”, 1 entry
- “TJ101 injection Reference Product”, 1 entry
Conditions, from the studies’ own filings
- Lung Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.